Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Significant Drop in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) was the recipient of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 37,641 shares, a drop of 62.2% from the August 15th total of 99,687 shares. Based on an average daily volume of 175,579 shares, the days-to-cover ratio is currently 0.2 days. Approximately 3.2% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research note on Monday, August 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Biorestorative Therapies alerts:

View Our Latest Stock Report on BRTX

Biorestorative Therapies Stock Down 3.3%

Shares of BRTX traded down $0.09 during trading on Friday, reaching $2.67. 10,281 shares of the company traded hands, compared to its average volume of 24,393. The stock has a 50-day simple moving average of $4.84 and a 200-day simple moving average of $5.43. The stock has a market cap of $3.68 million, a PE ratio of -0.12 and a beta of 0.83. Biorestorative Therapies has a twelve month low of $2.61 and a twelve month high of $34.60.

Institutional Trading of Biorestorative Therapies

Several institutional investors have recently added to or reduced their stakes in BRTX. Virtu Financial LLC lifted its stake in Biorestorative Therapies by 102.4% during the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after purchasing an additional 12,319 shares in the last quarter. DRW Securities LLC purchased a new position in shares of Biorestorative Therapies during the fourth quarter worth $55,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Biorestorative Therapies in the third quarter valued at $152,000. Institutional investors and hedge funds own 69.38% of the company’s stock.

About Biorestorative Therapies

(Get Free Report)

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.

Featured Stories

• Five stocks we like better than Biorestorative Therapies
• Planet Labs Has Fallen Back to Earth, But Wall Street Still Sees a Rebound
• As Homeowners’ Premiums Surge, This Insurer Is Posting Record Profits
• Nasdaq’s $100 Million Kraken Bet Prepares It for a Market That Never Closes
• Copper’s Record Rally Highlights a Deeper Supply Problem

Receive News & Ratings for Biorestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biorestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.